search
Back to results

Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)

Primary Purpose

FSHD, FSHD1, FSHD2

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
AOC 1020
Placebo
Sponsored by
Avidity Biosciences, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for FSHD focused on measuring FORTITUDE, Avidity, Avidity Biosciences, AOC 1020

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: FSHD1 or FSHD2 diagnosis confirmed by documented genetic testing (testing provided by Sponsor) Ambulatory and able to walk 10 meters (with or without assistive devices such as one cane, walking stick or braces) At least 1 muscle region suitable for biopsy (testing provided by Sponsor) Muscle weakness in both upper and lower body, as determined by Investigator Exclusion Criteria: Diagnosed with congenital or infantile FSHD Pregnancy, intent to become pregnant within 9 months after last planned dose of Study Drug, or active breastfeeding Unwilling or unable to continue to comply with contraceptive requirements Body mass index (BMI) >35.0 kg/m2 at Screening History of muscle biopsy within 30 days of the screening biopsy or planning to undergo any nonstudy muscle biopsies over the duration of the study History of bleeding disorders, significant keloid, or other skin or muscle conditions (e.g., severe muscle wasting) that, in the opinion of the Investigator, makes the participant unsuitable for serial muscle biopsy Anticipated survival less than 2 years Blood or plasma donation within 16 weeks of Study Day 1 Any contraindication to MRI Any abnormal lab values, conditions or diseases that, in the opinion of the investigator or Sponsor, would make the participant unsuitable for the study or could interfere with participation or completion of the study Treatment with any investigative medication within 1 month (or 5 half-lives of the drug, whichever is longer) of Screening

Sites / Locations

  • University of California, Irvine
  • University of California Los AngelesRecruiting
  • Stanford UniversityRecruiting
  • University of California San DiegoRecruiting
  • University of ColoradoRecruiting
  • University of FloridaRecruiting
  • Rare Disease ResearchRecruiting
  • Kansas University Medical CenterRecruiting
  • University of Minnesota
  • University of Rochester Medical CenterRecruiting
  • Duke University
  • Ohio State University
  • University of PennsylvaniaRecruiting
  • University of Texas SouthwesternRecruiting
  • University of Utah
  • Virginia Commonwealth UniversityRecruiting
  • University of Ottawa
  • Centre for Human Drug Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

AOC 1020 Regimen 1

AOC 1020 Regimen 2

AOC 1020 Regimen 3

Placebo (Saline)

Arm Description

Part A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months

Part B1 & C: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months

Part B2 & C: AOC 1020 Dose Regimen 3; Five doses administered intravenously over 9 months

Part A, B & C: Placebo; Five doses administered intravenously over 9 months

Outcomes

Primary Outcome Measures

Incidence of treatment-emergent adverse events

Secondary Outcome Measures

Plasma pharmacokinetic (PK) parameters of AOC 1020
Observed maximum concentration
Plasma pharmacokinetic (PK) parameters of AOC 1020
Observed half-life
Plasma pharmacokinetic (PK) parameters of AOC 1020
Observed area under the curve
Muscle drug concentration
Concentration of siRNA component in skeletal muscle
Urine drug concentration
Fraction of drug excreted in urine

Full Information

First Posted
February 17, 2023
Last Updated
October 4, 2023
Sponsor
Avidity Biosciences, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05747924
Brief Title
Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)
Acronym
FORTITUDE
Official Title
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 4, 2023 (Actual)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avidity Biosciences, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Detailed Description
AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in adult participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2). Part A is a dose titration design which includes a single and multiple dose schedule with 1 cohort. Part B is a single-ascending and multiple-ascending dose design with 2 cohorts. Part C is a parallel, multi-dose cohort design with 1 cohort. For each of Part A, B, and C the patient duration is 12 months as the active treatment period is approximately 9 months followed by a 3-month follow-up period. Once participants have completed active treatment and the follow-up period, they may have the option to participate in a planned open-label extension. If patients do not enroll in the open-label extension, they will be followed through a 6-month safety follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Keywords
FORTITUDE, Avidity, Avidity Biosciences, AOC 1020

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AOC 1020 Regimen 1
Arm Type
Experimental
Arm Description
Part A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
Arm Title
AOC 1020 Regimen 2
Arm Type
Experimental
Arm Description
Part B1 & C: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
Arm Title
AOC 1020 Regimen 3
Arm Type
Experimental
Arm Description
Part B2 & C: AOC 1020 Dose Regimen 3; Five doses administered intravenously over 9 months
Arm Title
Placebo (Saline)
Arm Type
Placebo Comparator
Arm Description
Part A, B & C: Placebo; Five doses administered intravenously over 9 months
Intervention Type
Drug
Intervention Name(s)
AOC 1020
Intervention Description
AOC 1020 will be administered via intravenous (IV) infusion
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline
Intervention Description
Placebo will be administered via intravenous (IV) infusion
Primary Outcome Measure Information:
Title
Incidence of treatment-emergent adverse events
Time Frame
Through study completion, up to Day 365
Secondary Outcome Measure Information:
Title
Plasma pharmacokinetic (PK) parameters of AOC 1020
Description
Observed maximum concentration
Time Frame
Through study completion; up to Day 365
Title
Plasma pharmacokinetic (PK) parameters of AOC 1020
Description
Observed half-life
Time Frame
Through study completion; up to Day 365
Title
Plasma pharmacokinetic (PK) parameters of AOC 1020
Description
Observed area under the curve
Time Frame
Through study completion; up to Day 365
Title
Muscle drug concentration
Description
Concentration of siRNA component in skeletal muscle
Time Frame
Day 120
Title
Urine drug concentration
Description
Fraction of drug excreted in urine
Time Frame
0 - 24 hours after first and third dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: FSHD1 or FSHD2 diagnosis confirmed by documented genetic testing (testing provided by Sponsor) Ambulatory and able to walk 10 meters (with or without assistive devices such as one cane, walking stick or braces) At least 1 muscle region suitable for biopsy (testing provided by Sponsor) Muscle weakness in both upper and lower body, as determined by Investigator Exclusion Criteria: Diagnosed with congenital or infantile FSHD Pregnancy, intent to become pregnant within 9 months after last planned dose of Study Drug, or active breastfeeding Unwilling or unable to continue to comply with contraceptive requirements Body mass index (BMI) >35.0 kg/m2 at Screening History of muscle biopsy within 30 days of the screening biopsy or planning to undergo any nonstudy muscle biopsies over the duration of the study History of bleeding disorders, significant keloid, or other skin or muscle conditions (e.g., severe muscle wasting) that, in the opinion of the Investigator, makes the participant unsuitable for serial muscle biopsy Anticipated survival less than 2 years Blood or plasma donation within 16 weeks of Study Day 1 Any contraindication to MRI Any abnormal lab values, conditions or diseases that, in the opinion of the investigator or Sponsor, would make the participant unsuitable for the study or could interfere with participation or completion of the study Treatment with any investigative medication within 1 month (or 5 half-lives of the drug, whichever is longer) of Screening
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amy Halseth, PhD
Phone
858-771-7038
Email
medinfo@aviditybio.com
Facility Information:
Facility Name
University of California, Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92697
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of California Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Name
University of California San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Colorado
City
Denver
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32608
Country
United States
Individual Site Status
Recruiting
Facility Name
Rare Disease Research
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Individual Site Status
Recruiting
Facility Name
Kansas University Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Individual Site Status
Recruiting
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27708
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43221
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Texas Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Ottawa
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4E9
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Centre for Human Drug Research
City
Leiden
Country
Netherlands
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.aviditybiosciences.com/
Description
Avidity Biosciences Website
URL
https://fortitude-study.com/
Description
FORTITUDE Study Website

Learn more about this trial

Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)

We'll reach out to this number within 24 hrs